Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trial.

MLA

Voskens, Caroline J., et al. “Safety and Tolerability of a Single Infusion of Autologous Ex Vivo Expanded Regulatory T Cells in Adults with Ulcerative Colitis (ER-TREG 01): Protocol of a Phase 1, Open-Label, Fast-Track Dose-Escalation Clinical Trial.” BMJ Open, vol. 11, no. 12, Dec. 2021, p. e049208. EBSCOhost, https://doi.org/10.1136/bmjopen-2021-049208.

APA

Voskens, C. J., Stoica, D., Roessner, S., Vitali, F., Zundler, S., Rosenberg, M., Wiesinger, M., Wunder, J., Siegmund, B., Schuler-Thurner, B., Schuler, G., Berking, C., Atreya, R., & Neurath, M. F. (2021). Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trial. BMJ Open, 11(12), e049208. https://doi.org/10.1136/bmjopen-2021-049208

Chicago

Voskens, Caroline J, Diane Stoica, Susanne Roessner, Francesco Vitali, Sebastian Zundler, Marita Rosenberg, Manuel Wiesinger, et al. 2021. “Safety and Tolerability of a Single Infusion of Autologous Ex Vivo Expanded Regulatory T Cells in Adults with Ulcerative Colitis (ER-TREG 01): Protocol of a Phase 1, Open-Label, Fast-Track Dose-Escalation Clinical Trial.” BMJ Open 11 (12): e049208. doi:10.1136/bmjopen-2021-049208.